OUP, Celgene and Astellas Venture Management all supplied a portion of the funding to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.

UW-founded cancer immunotherapy developer Neoleukin Therapeutics will merge with Aquinox in an all-share deal giving the spinout's shareholders roughly 38.6% equity in the new company.

The consumer rewards app developer is now valued at $1bn following a series D round of undisclosed size that was led by Koch Disruptive Technologies.

Hewlett Packard Enterprise reportedly paid less than $50m for the assets of Qualcomm Ventures and CapitalG-backed MapR, which had once been valued at more than $1bn.

3-V Biosciences has changed its name to Sagimet Biosciences after closing a series E round backed by strategic partner Ascletis at $25m.

Seed development technology provider Inari increased its funding to $144m altogether, with Campbell Soup's Acre Venture Partners returning to reinvest.

Existing investor McKesson Ventures co-led the $22.5m round, which will enable IVX Health to open additional infusion and injection therapies centres.

Having helped build teams for Citadel for seven years, Jenny Lee has come to Softbank Investment Advisers to manage human resources following the launch of its second Vision Fund.

Materials and hardtech will be focuses for the CVC unit, says MD Nicolas Sauvage.

Various SoftBank entities have put a total of $200m into Cybereason, doubling the cybersecurity technology provider’s total equity funding to about $400m.